The upward trajectory of the single-use bioreactors market is being significantly fueled by the increased production of monoclonal antibodies and recombinant proteins. These bioreactors are becoming increasingly integral to the clinical production of monoclonal antibodies due to their efficiency and reliability.
Moreover, the expansion in the vaccine sector is adding further momentum to the...